Search our Database of Scientific Publications and Authors

I’m looking for a

    1125 results match your criteria Clinical Genitourinary Cancer [Journal]

    1 OF 23

    Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
    Clin Genitourin Cancer 2017 Nov 1. Epub 2017 Nov 1.
    Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY.
    Background: Patients with exclusive bone metastatic spread from urothelial carcinoma (UC) throughout their disease course represent a rare subgroup with unique clinical features. These patients deserved special consideration in a retrospective multicenter study.

    Patients And Methods: Analyses were made from a pool of 1911 patients with a diagnosis of metastatic UC, from 23 centers. Read More

    Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.
    Clin Genitourin Cancer 2017 Oct 17. Epub 2017 Oct 17.
    Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:
    Background: Squamous cell carcinoma (SCC) is an uncommon histologic subtype of bladder cancer with limited data on treatment patterns, outcomes, and prognostic factors. "Real world" information might inform decision-making, prognostic estimates, and clinical trial designs.

    Patients And Methods: A retrospective review of patients with tissue-confirmed bladder SCC treated at Cleveland Clinic from 2007 to 2016 was performed. Read More

    Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
    Clin Genitourin Cancer 2017 Oct 24. Epub 2017 Oct 24.
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Prostate and Urological Cancers Program, Yale Comprehensive Cancer Center, New Haven, CT.
    Background: Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown.

    Patients And Methods: Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Read More

    Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.
    Clin Genitourin Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Department of Urology, Columbia University Medical Center, New York, NY.
    Background: To compare oncologic outcomes of different definitive treatment (DT) modalities in a cohort of patients with prostate cancer (PCa) after active surveillance (AS).

    Methods: We identified 237 patients with National Comprehensive Cancer Network (NCCN) low- and intermediate-risk prostate cancer diagnosed from 1990 to 2012 who did not undergo immediate DT within 12 months of diagnosis (ie, AS patients as well as watchful waiting and those refusing DT). Charts were examined for clinical/pathologic data and type of DT: surgery (RP), radiation including brachytherapy (XRT), cryotherapy, and androgen deprivation therapy monotherapy (ADT). Read More

    Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy.
    Clin Genitourin Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. Electronic address:
    Purpose: To evaluate the utilization of pelvic lymph node dissection (PLND) and its extent in contemporary US patients, and to correlate it to the detection of pN1 disease.

    Patients And Methods: A total of 328,710 individuals who received radical prostatectomy between the years 2004 and 2013 were identified within the National Cancer Data Base. The Cochran-Armitage test was used to assess the statistical significance of temporal trends. Read More

    Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.
    Clin Genitourin Cancer 2017 Oct 17. Epub 2017 Oct 17.
    Moffitt Cancer Center, Tampa, FL.
    Purpose: To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma.

    Patients And Methods: We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2000 to May 2015. LND was performed in 187 patients (63. Read More

    Female Urethra Adenocarcinoma.
    Clin Genitourin Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Department of Urology, University Hospital "Ospedali Riuniti", Ancona, Italy.
    Female urethra adenocarcinoma (FUA) is a rare aggressive tumor that occurs in Skene ducts and glands. It is associated with a relatively poor prognosis. The aim of this review was to evaluate FUA in terms of epidemiology, risk factors, diagnosis, natural history of disease, modalities of treatment, and outcomes. Read More

    Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis.
    Clin Genitourin Cancer 2017 Sep 25. Epub 2017 Sep 25.
    Department of Urology, University of California, San Diego, School of Medicine, La Jolla, CA. Electronic address:
    Background: Sunitinib might optimize the feasibility of partial nephrectomy (PN) for complex renal tumors with imperative indications. We compared the renal functional outcomes of patients with complex renal masses who had undergone sunitinib before PN with those of patients who had not required neoadjuvant sunitinib before PN.

    Patients And Methods: We performed a multicenter retrospective analysis of patients with renal cell carcinoma who had undergone PN for a complex renal mass (R. Read More

    Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
    Clin Genitourin Cancer 2017 Oct 7. Epub 2017 Oct 7.
    Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
    Background: Limited information is available regarding the use of androgen receptor (AR) immunohistochemical expression in muscle-invasive or metastatic urothelial carcinoma. We aimed to evaluate the frequency of AR expression by tumor cells (TC), its prognostic role, and its relationship with programmed cell-death ligand 1 (PD-L1) expression in these patients.

    Patients And Methods: From September 2015 to January 2017, we collected tissue from patients who received platinum-based chemotherapy at our center. Read More


    Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey.
    Clin Genitourin Cancer 2017 Oct 5. Epub 2017 Oct 5.
    Carolina Urologic Research Center, Myrtle Beach, SC.
    Background: Bone metastases in men with prostate cancer are often initially asymptomatic, resulting in delayed identification, diagnosis, and appropriate treatment. To assess how patients with advanced prostate cancer (aPC) communicate symptoms to health care providers, an international patient survey was conducted.

    Methods: An online and phone survey was conducted by Harris Poll in 11 countries (Brazil, France, Germany, Japan, Italy, Netherlands, Singapore, Spain, Taiwan, United Kingdom, United States) from February 12 to October 27, 2015, in men with aPC (ie, those who reported as having PC beyond the prostate [metastatic]) and their caregivers. Read More

    Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
    Clin Genitourin Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Department of Urology, Indiana University School of Medicine, Indianapolis, IN.
    Background: Patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk testicular cancer might receive either 4 cycles of etoposide and cisplatin (EP × 4) or 3 cycles of bleomycin, etoposide, and cisplatin (BEP × 3). We sought to examine differences in survival after retroperitoneal lymph node dissection (PC-RPLND) between patients who received EP × 4 compared with BEP × 3.

    Patients And Methods: The Indiana University Testis Cancer database was queried to identify IGCCCG good-risk PC-RPLND patients who received either EP × 4 or BEP × 3 induction chemotherapy. Read More

    Benefits of Urologic-Dermatologic Consultations for the Diagnosis of Cutaneous Penile Lesions: A Prospective Study.
    Clin Genitourin Cancer 2017 Oct 5. Epub 2017 Oct 5.
    Department of Urology, Angers University Hospital, Angers, France.
    Introduction: We evaluated the benefits of a specialized consultation created in 2014 for cutaneous penile lesions.

    Materials And Methods: We performed a descriptive prospective study evaluating all patients sent for a monthly urologic-dermatologic consultation at a French university hospital from September 2014 to September 2015 for cutaneous penile lesions. All patients evaluated were included. Read More

    The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Department of Oncology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
    Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Read More

    Retroperitoneal Robot-Assisted Versus Open Partial Nephrectomy for cT1 Renal Tumors: A Matched-Pair Comparison of Perioperative and Early Oncological Outcomes.
    Clin Genitourin Cancer 2017 Oct 3. Epub 2017 Oct 3.
    Department of Urology, University of Bologna, Bologna, Italy; Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy.
    Background: The objective of this study was to compare perioperative and early oncological outcomes of a matched cohort of patients who underwent retroperitoneal robot-assisted partial nephrectomy (RP-RAPN) and open partial nephrectomy (OPN) for clinically localized renal tumors.

    Patients And Methods: We performed a retrospective analysis of patients who underwent RP-RAPN and OPN treated at 2 referral centers from January 2011 to December 2015. We focused on the following postoperative outcomes: warm ischemia time (WIT), operative time, blood loss, intra- and postoperative complications, estimated glomerular filtration rate (eGFR), hospital stay, and positive surgical margins. Read More

    Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.
    Clin Genitourin Cancer 2017 Sep 25. Epub 2017 Sep 25.
    Department of Pharmacy, University Hospital, Besançon, France; University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, Besançon, France. Electronic address:
    Purpose: To describe factors associated with overall survival (OS) among patients with metastatic clear-cell renal-cell carcinoma (mccRCC) in regard to evolution of systemic therapies.

    Patients And Methods: Two hundred twenty-four consecutive patients with histologically confirmed mccRCC who received targeted therapy on first-line treatment between January 2007 and March 2015 were included. The primary end point was OS for metastatic first-line or second-line treatment. Read More

    Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Clin Genitourin Cancer 2017 Sep 23. Epub 2017 Sep 23.
    Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
    Introduction: External beam radiation therapy (EBRT) with short-term androgen deprivation therapy is the standard of care for intermediate-risk prostate cancer patients. However, no study to date has evaluated the hormonal kinetics or sexual and hormonal function recovery after cessation of short-term luteinizing hormone (LH)-releasing hormone (LHRH) antagonist treatment.

    Patients And Methods: Ten intermediate-risk prostate cancer patients (mean age, 69. Read More

    Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Clin Genitourin Cancer 2017 Sep 23. Epub 2017 Sep 23.
    Department of Urology, Chiba Cancer Center Hospital, Chiba, Japan.
    Background: Abiraterone (AA) and enzalutamide (ENZA) are increasingly being used in chemotherapy-naive patients with metastatic castration-resistant prostate cancer owing to efficacy and favorable toxicity. However, the order in which they should be administered has not been determined.

    Patients And Methods: We retrospectively reviewed the records of chemotherapy-naive patients with metastatic castration-resistant prostate cancer who had received sequential treatment with either AA followed by ENZA (AA-ENZA) or the converse (ENZA-AA). Read More

    Frequency and Markers of Precursor Lesions and Implications for the Pathogenesis of Testicular Germ Cell Tumors.
    Clin Genitourin Cancer 2017 Sep 5. Epub 2017 Sep 5.
    Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark.
    Background: The World Health Organization classification of urologic cancer 2016 describes 3 noninvasive precursor lesions for testicular germ cell tumor type II (TGCT) of young adults. Germ cell neoplasia in situ is the initial precursor lesion. Intratubular seminoma (ITSE), and intratubular embryonal carcinoma (ITEC) are 2 intermediate precursor lesions. Read More

    Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies.
    Clin Genitourin Cancer 2017 Sep 8. Epub 2017 Sep 8.
    Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:
    Background: Screen failures, defined as individuals who undergo screening but are not enrolled in a clinical trial, incur significant costs without contributing valuable data to the study. Despite these costs, there are few published data about the rate or reasons for screen failures in advanced genitourinary cancer clinical trials.

    Materials And Methods: We reviewed 50 phase II and III trials in advanced genitourinary cancers conducted between 1999 and 2016. Read More

    Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
    Purpose: To analyze how prostate-specific antigen (PSA) screening and practice patterns has affected trends in tumor characteristics in men undergoing radical prostatectomy (RP) in the United States and Denmark. Unlike in the United States, PSA screening has not been recommended in Denmark.

    Patients And Methods: We performed an observational register study using pre- and postoperative data on 2168 Danish patients from Rigshospitalet, Copenhagen, Denmark, and 2236 patients from Stanford University Hospital, Stanford, CA, who underwent RP between 1995 and 2013. Read More

    Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.
    Clin Genitourin Cancer 2017 Sep 7. Epub 2017 Sep 7.
    Foundation Medicine Inc, Cambridge, MA.
    Purpose: Tumor genomic profiling helps direct therapy for advanced urothelial carcinoma (UC). In the course of clinical care, we encountered a patient with a complete loss of SMARCB1 (switch/sucrose nonfermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), which encodes INI-1 (integrase interactor 1), as the sole detected driver of their urinary tract tumor. Our objective was the identification and genomic characterization of urinary tract neoplasia with complete SMARCB1 loss. Read More

    Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer.
    Clin Genitourin Cancer 2017 Sep 8. Epub 2017 Sep 8.
    Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada.

    National Trends and Predictors of Organ-sparing for Invasive Penile Tumors: Expanding the Therapeutic Window.
    Clin Genitourin Cancer 2017 Sep 8. Epub 2017 Sep 8.
    Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL.
    Introduction: The purpose of this study was to analyze contemporary trends and predictors in the use of organ-sparing treatment (OST) for low-stage invasive penile tumors as well as to ascertain its impact on overall mortality (OM) in those with high-risk (pT2) disease.

    Patients And Methods: The National Cancer Data Base was queried for patients with clinically nonmetastatic penile cancer and available pathologic tumor (pT) and treatment data from 1998 to 2012. Independent predictors for performance of OST were analyzed. Read More

    Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Cologne, Germany. Electronic address:
    Introduction: The management of testicular cancer (TC) requires a complex multimodal therapeutic approach. Despite the availability of regularly updated guidelines, non-guideline-concordant treatment of TC still occurs. The purpose of the present study was to evaluate the compliance patterns in diagnosis and therapy and their potential effects on patient outcomes with respect to the guidelines of the European Association of Urology. Read More

    Sex-Specific Prognostic Significance of Obesity in Nonmetastatic Clear-Cell Renal-Cell Carcinoma in Korea: A Large Multicenter Cohort Analysis.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Department of Urology, College of Medicine, Hallym University, Chuncheon, Korea. Electronic address:
    Introduction: We assessed the prognostic significance of obesity in relation to sex in patients with nonmetastatic clear-cell renal-cell carcinoma (nm-cRCC) in a large multicenter setting in Korea.

    Patients And Methods: A total of 2097 patients with nm-cRCC who underwent surgery with curative intent were enrolled from 6 institutions in Korea between April 2000 and February 2014. Obesity was determined by body mass index (BMI) before surgery. Read More

    Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address:
    Background: Antiandrogen withdrawal syndrome (AAWS), manifested as a prostate-specific antigen (PSA) decline after discontinuation of a first-generation antiandrogen has been well characterized. The objective of the present study was to assess the incidence of AAWS with enzalutamide in men with metastatic castration-resistant prostate cancer.

    Patients And Methods: Patients from a single-institution cohort with metastatic castration-resistant prostate cancer who had discontinued enzalutamide after PSA or radiographic progression were included. Read More

    National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX. Electronic address:
    Purpose: Management of cT4b bladder cancer is poorly defined; national guidelines recommend chemotherapy (CT) alone or chemoradiation (CRT). Using a large, contemporary dataset, we evaluated national practice patterns as well as associated outcomes, especially with respect to radical cystectomy (RC) and CRT versus CT alone.

    Methods: The National Cancer Data Base was queried (2004-2013) for patients diagnosed with cT4bN0-3M0 bladder cancer. Read More

    Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients.
    Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.
    Keck School of Medicine, Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address:
    Background: Cisplatin eligibility for clinical trials has been defined as glomerular filtration rate (GFR) ≥ 60 mL/min due to the risk of nephrotoxicity in patients with renal impairment. For urothelial cancer, substitution of carboplatin instead of cisplatin compromises outcomes. We evaluated change in GFR in patients treated with cisplatin despite baseline GFR < 60 mL/min to determine risk of nephrotoxicity. Read More

    Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Department of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland. Electronic address:
    Background: The aim was to evaluate quality of life (QoL), pain, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with different regimens after first-line docetaxel, as well as disease progression.

    Patients And Methods: Patients with mCRPC having received first-line chemotherapy with docetaxel were eligible. Second-line treatment choice was at the discretion of the local investigator. Read More

    Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.
    Clin Genitourin Cancer 2017 Sep 4. Epub 2017 Sep 4.
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:
    Objective: To examine the impact of granulocyte-colony stimulating factor (G-CSF) use on the incidence and severity of bleomycin-induced pneumonitis (BIP) in patients with germ cell tumor (GCT) receiving first-line chemotherapy.

    Patients And Methods: Clinical data from our institutional GCT database was complemented by review of radiology, pharmacy, and medical records. All patients receiving first line chemotherapy between January 1, 2000 and December 31, 2010 were included. Read More

    Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer.
    Clin Genitourin Cancer 2017 Sep 5. Epub 2017 Sep 5.
    Division of Urology, McGill University, Montreal, Canada. Electronic address:
    Introduction: Late locoregional complications in prostate cancer (PCa) affect quality of life and require medical interventions. Our objective was to compare late locoregional complications in men dying of castration-resistant PCa (CRPC) who previously received external-beam radiotherapy (EBRT) to radical prostatectomy (RP). No group without previous primary local treatment was included. Read More

    Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy.
    Clin Genitourin Cancer 2017 Aug 31. Epub 2017 Aug 31.
    Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany.
    Background: The aim of this study was to compare 11 active surveillance (AS) protocols in contemporary European men treated with radical prostatectomy (RP) at the Martini-Clinic Prostate Cancer Center.

    Patients And Methods: Analyzed were 3498 RP patients, from 2005 to 2016, who underwent ≥ 10 core biopsies and fulfilled at least 1 of 11 examined AS entry definitions. We tested proportions of AS eligibility, ineligibility, presence of primary Gleason 4/5, upstage, and combinations thereof at RP, as well as 5-year biochemical recurrence-free survival (BFS). Read More

    Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address:
    Background: Twelve percent of newly diagnosed prostate cancers in the United States are node-positive. In a setting of disparate treatment guideline recommendations for node-positive disease, this study describes the treatment patterns for clinical node-positive (cN(+)) and pathologic node-positive (pN(+)) patients across the United States. MATERIALS AND METHODS: Using the National Cancer Data Base, men diagnosed with cN(+) or pN(+) disease were identified from 2006 to 2011. Read More

    Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:
    Background: Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and impact on survival of VTE in patients with locoregional UTT. Read More

    Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database.
    Clin Genitourin Cancer 2017 Aug 12. Epub 2017 Aug 12.
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:
    Background: Poor-risk patients with metastatic renal-cell carcinoma remain poorly characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive analysis of this patient population, defined by 3 widely used prognostic models, treated with targeted therapy.

    Patients And Methods: We conducted a pooled retrospective analysis of 4736 metastatic renal-cell carcinoma patients treated on phase 2 and 3 clinical trials. Read More

    External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Department for Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.
    Background: We sought to externally validate our pathologic nodal staging score (pNSS) model, which allows for quantification of the likelihood that a pathologically node-negative patient will not have lymph node (LN) metastasis after radical prostatectomy for prostate cancer (PCa) in a population-based cohort.

    Patients And Methods: We analyzed data from 50,598 patients treated with radical prostatectomy and pelvic LN dissection using the Surveillance, Epidemiology, and End Results database. We estimated the sensitivity of pathologic nodal staging using a β-binomial model and developed a novel pNSS model, which represents the probability that a patient's PCa has been correctly staged as node negative as a function of the number of examined LNs. Read More

    Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease.
    Clin Genitourin Cancer 2017 Aug 31. Epub 2017 Aug 31.
    GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA. Electronic address:
    Background: Men who present with metastatic disease can have de novo or primary progressive disease. We characterized and compared the outcomes between these 2 groups.

    Patients And Methods: A retrospective cross-sectional analysis from a single institution of de novo versus primary progressive metastatic patients during a 2-year consecutive period was undertaken. Read More

    Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer.
    Clin Genitourin Cancer 2017 Aug 24. Epub 2017 Aug 24.
    Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:
    Introduction: Knowledge of the comparative oncologic outcomes of histologic variants after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) relies on small case series. We compared the effect of pure squamous cell carcinoma, adenocarcinoma, and neuroendocrine carcinoma compared with pure urothelial carcinoma (PUC) on overall survival (OS) and pathologic tumor, lymph node, and surgical margin status after RC.

    Patients And Methods: Using the National Cancer Database, we retrospectively examined patients undergoing RC for MIBC from 2003 to 2011. Read More

    Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on (68)Ga-PSMA and (18)F-FDG PET/CT: A Case Report and Review of the Literature.
    Clin Genitourin Cancer 2017 Aug 23. Epub 2017 Aug 23.
    Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, the University of Melbourne, Parkville, Victoria, Australia.

    Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.
    Clin Genitourin Cancer 2017 Aug 12. Epub 2017 Aug 12.
    Department of Medical Oncology, Gustave Roussy, Villejuif, France.
    Background: Everolimus (E) and axitinib (A) have been standard treatments for patients with metastatic renal cell carcinoma after failure of first-line therapy (1L) with vascular endothelial growth factor-targeted therapy. This study aims to compare both drugs in a large comprehensive cancer center.

    Methods: Patient characteristics and outcome data from all patients with metastatic renal cell carcinoma who received E or A as second-line therapy at Gustave Roussy from April 2007 to May 2015 have been recorded. Read More

    Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Clin Genitourin Cancer 2017 Aug 3. Epub 2017 Aug 3.
    Department of Urology, Chiba University Hospital, Chiba, Japan.
    Introduction: Reductions in testosterone concentration play a significant role in the treatment of prostate cancer. We studied the role of testosterone as a prognostic marker for advanced prostate cancer (stage C or higher) treated with primary androgen-deprivation therapy (ADT).

    Patients And Methods: A total of 348 patients were treated using ADT as first-line therapy for prostate cancer at Chiba University Hospital between 1999 and 2016. Read More

    Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
    Clin Genitourin Cancer 2017 Aug 9. Epub 2017 Aug 9.
    Department of Antitumor Drug Therapy, Rostov Research Institute of Oncology, Rostov-on-Don, Russia.
    Background: The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population.

    Patient And Methods: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St. Read More

    1 OF 23